Patents for A61P 35 - Antineoplastic agents (221,099)
07/2002
07/04/2002US20020086815 Cancer therapy; for skin cancer, myeloids
07/04/2002US20020086420 Novel antiangiogenic peptides
07/04/2002US20020086411 Defective adenovirus for use in the treatment of tumors
07/04/2002US20020086408 Ubiquitin-like conjugating protein
07/04/2002US20020086403 Polypeptide for use in the treatment and prevention of viral infections and cancer
07/04/2002US20020086380 Enzymatic polypeptide for use in animal feeds and in generating chemical intermediates for vitamin A
07/04/2002US20020086352 Methods for expressing endostatin protein
07/04/2002US20020086316 Reagents and methods useful for detecting diseases of the prostate
07/04/2002US20020086315 Method of determining a chemotherapeutic regimen based on ERCC1 expression
07/04/2002US20020086284 Determining sensitivity of a cell to reovirus infection; obtain cells, monitor ras protein signaling, consistent signaling indicates sensitivity to reovirus infection
07/04/2002US20020086063 Cord blood-derived activated lymphocytes, preparations containing said lymphocytes as main ingredient and method and kit for producing said preparations
07/04/2002US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating
07/04/2002US20020086051 For delivering drug directly to interior portions of the body of a mammalian organism, such as to the eye
07/04/2002US20020086037 For use in therapy of bacterial infections, cancer; in vaccines
07/04/2002US20020086018 Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
07/04/2002US20020086012 Costimulation of t-cell proliferation by a chimeric bispecific costimulatory protein
07/04/2002US20020086007 Angiogenesis-inhibiting peptides and proteins and methods of use
07/04/2002US20020085997 Tumor cells at least some of which contain at least one MHC-I-haplotype of the patient on the cell surface, and which are charged with one or more peptides binding to the MHC-I molecule
07/04/2002US20020085615 Differential scanning calorimeter
07/04/2002DE10065710A1 Arzneimittel enthaltend ein Polyamin als Wirksubstanz A medicament comprising a polyamine as the active substance
07/04/2002DE10065482A1 New heavier halogen atom substituted squarane dyes, used as photosensitizer in photodynamic therapeutical applications, fluorescent detector of tumors and sensitizer in water sterilization
07/04/2002DE10065043A1 Carbonsäureamide, diese Verbindungen enthaltene Arzneimittel, deren Verwendung und Herstellung Carboxamides, medicines, these compounds contained, their use and production
07/04/2002DE10064994A1 Sulfamidothienopyrimidine Sulfamidothienopyrimidine
07/04/2002DE10063435A1 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Chinazolinderviate, medicaments containing these compounds, their use and process for their preparation
07/04/2002DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases
07/04/2002CA2782510A1 Polypeptides
07/04/2002CA2436739A1 Combination agent
07/04/2002CA2433116A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
07/04/2002CA2433100A1 Indole derivatives as ligands of thyroid receptors
07/04/2002CA2432683A1 Screening method based on siah-numb interaction
07/04/2002CA2432570A1 New clinical treatment
07/04/2002CA2432542A1 Methods of modulating toll-related receptor (trr) signaling
07/04/2002CA2432536A1 Angiogenesis inhibitor
07/04/2002CA2432518A1 Treatment of inoperable tumors by stereotactic injection of microspheres
07/04/2002CA2432214A1 Gene involved in apoptosis regulation
07/04/2002CA2432168A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
07/04/2002CA2431916A1 New therapeutic uses of smr1 peptides
07/04/2002CA2431913A1 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
07/04/2002CA2431471A1 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
07/04/2002CA2430691A1 Immunomodulatory polynucleotides and methods of using the same
07/03/2002EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1)
07/03/2002EP1219632A1 Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds
07/03/2002EP1219599A1 Vitamin d derivatives having substituents at the 2 alpha-position
07/03/2002EP1219305A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
07/03/2002EP1219180A1 Cancer chemoprotective food products
07/03/2002EP1218544A1 Methods for identifying rna binding compounds
07/03/2002EP1218538A2 Cancer associated antigens and uses therefor
07/03/2002EP1218527A2 Adenoviral vectors for treating disease
07/03/2002EP1218521A1 Use of soluble costimulatory factor for tumor immuno-gene therapy
07/03/2002EP1218518A1 Dna polymerase lambda and uses thereof
07/03/2002EP1218514A1 Designing immunogens
07/03/2002EP1218509A2 Fibroblast growth factor-like polypeptides
07/03/2002EP1218506A1 Traf4 associated cell cycle proteins, compositions and methods of use
07/03/2002EP1218504A2 Gl50 molecules and uses therefor
07/03/2002EP1218496A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR
07/03/2002EP1218494A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
07/03/2002EP1218493A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
07/03/2002EP1218414A2 Polypeptides for detection and elimination of ca19-9 antigen positive cells
07/03/2002EP1218413A2 Engineering antibodies that bind irreversibly
07/03/2002EP1218412A2 Human g-protein coupled receptor
07/03/2002EP1218408A1 32 human secreted proteins
07/03/2002EP1218406A1 Nucleic acids and secreted polypeptides encoded thereby
07/03/2002EP1218404A1 A binding motif of a receptor
07/03/2002EP1218402A1 Novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
07/03/2002EP1218398A1 Antisense modulation of pi3 kinase p110 beta expression
07/03/2002EP1218397A1 Attractin-like polynucleotides, polypeptides, and antibodies
07/03/2002EP1218395A1 Antisense modulation of x-linked inhibitor of apoptosis expression
07/03/2002EP1218393A1 Cell targeting compositions and methods of using the same
07/03/2002EP1218376A1 Tyrosine kinase inhibitors
07/03/2002EP1218375A1 Pharmaceutically active sulfonyl amino acid derivatives
07/03/2002EP1218374A1 Pharmaceutically active sulfonamide derivatives
07/03/2002EP1218373A2 2-pyrazolin-5-ones as tyrosine kinase inhibitors
07/03/2002EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
07/03/2002EP1218368A1 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
07/03/2002EP1218361A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents
07/03/2002EP1218358A1 Therapeutic quinazoline compounds
07/03/2002EP1218357A1 Quinazoline derivatives
07/03/2002EP1218356A1 Quinazoline compounds and pharmaceutical compositions containing them
07/03/2002EP1218355A1 Therapeutic quinazoline derivatives
07/03/2002EP1218354A1 Quinazoline derivatives and their use as pharmaceuticals
07/03/2002EP1218348A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
07/03/2002EP1218347A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
07/03/2002EP1218342A2 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
07/03/2002EP1218333A1 Anti-inflammatory nitro- and thia- fatty acids
07/03/2002EP1218032A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
07/03/2002EP1218025A1 Use of mullerian inhibiting substance for treating excess androgen states
07/03/2002EP1218019A2 Oncolytic virus
07/03/2002EP1218013A2 Phospholipid prodrugs of anti-proliferative drugs
07/03/2002EP1218006A2 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
07/03/2002EP1218005A2 Vitronectin receptor antagonists
07/03/2002EP1218004A2 Use of cell membrane penetrating indigoid bisindole derivatives
07/03/2002EP1218000A1 Anti-cancer nitro- and thia-fatty acids
07/03/2002EP1217990A1 Cationic dosper virosomes
07/03/2002EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery
07/03/2002EP0983234B1 Leukotriene b 4 derivatives, in particular 7-methylcyclohexyl-ltb 4 antagonists
07/03/2002EP0935468B1 Use of cytokines and cytotoxic substances in a new method to treat tumors
07/03/2002EP0912085A4 Precise efficacy assay methods for active agents including chemotherapeutic agents
07/03/2002EP0897389B1 Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
07/03/2002EP0813423B1 Composition to inhibit osteolysis and metastasis
07/03/2002EP0681573B1 C2 Taxane derivatives and pharmaceutical compositions containing them